维普中文期刊产品整合服务
2篇 您的检索式:作者名="R.F. Casper"
    题名 作者 年代 出处 被引量
1来曲唑或克罗米芬治疗不孕后怀孕的911例新生儿中的先天性畸形分析显示文摘Objective: To evaluate the incidence of congenital malformations among offspring of mothers who conceived with clomiphene citrate(CC) or with letrozole treatment for infertility. Design: Retrospective study. Setting: 5 fertility centers in Canada. Patients: 911 newborns from women who conceived following CC or letrozole treatment. Interventions: Examination of medical files of both mother and newborn, and cross-checked with the parents by telephone calls. Main Outcome Measures: Identified major and minor congenital malformations, birth weight, age of the mother, and type of treatment that led to the conception. Results: Overall, congenital malformations and chromosomal abnormalities were found in 14 of 514 newborns in the letrozole group(2.4%) and in 19 of 397 newborns in the CC group(4.8%). The major malformation rate in the letrozole group was 1.2%(6/514) and in the CC group was 3.0%(12/397). One newborn in the letrozole group was found to have a ventricular septal defect(0.2%)-compared to 4 newborns in the CC group(1.0%). In addition, the rate of all congenital cardiac anomalies was significantly higher(P: 0.02) in the CC group(1.8%) compared to the letrozole group(0.2%). Conclusion: There was no difference in the overall rates of major and minor congenital malformations among newborns from mothers who conceived after letrozole or CC treatments. However, it appears that congenital cardiac anomaly is less frequent in the letrozole group. The concern that letrozole use for ovulation induction could be teratogenic is unfounded based on our data.Tulandi T. Martin J. Al-Fadhli R. R.F. Casper 李跃萍 2006世界核心医学期刊文摘(妇产科学分册)2006,0,10:2
2醋酸亮丙瑞林和激素反向添加治疗伴慢性盆腔痛的IV期子宫内膜异位症10年显示文摘This pilot study examined the effect of a low-dose E and pulsed progestogen hormone therapy (HT) regimen for add-back during long-term GnRH-agonist therapy on bone mineral density (BMD) in five patients with stage IV endometriosis. Bone mineral density was stable after initiation of HT for the entire follow-up period (up to 10 years). One patient stopped her treatment on two occasions to conceive and was successful each time with delivery of a normal baby. No patient had return of pelvic pain after HT add-back.Bedaiwy M.A. Casper R.F. 张旸 2006世界核心医学期刊文摘(妇产科学分册)2006,0,11:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费